RCS - Allergy Therapeutics - Allergy Therapeutics at EAACI Congress 2022

Allergy TherapeuticsAnnouncement

01/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220701:nRSA9252Qa&default-theme=true

RNS Number : 9252Q  Allergy Therapeutics PLC  01 July 2022

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of
the European Academy of Allergy and Clinical Immunology (EAACI) 2022

 

1 July 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty
pharmaceutical company specialising in allergy immunotherapy, today announces
that the Group will be sharing key scientific findings from across its
research portfolio at the upcoming European Academy of Allergy and Clinical
Immunology (EAACI) Hybrid Congress, taking place from today until 3 July 2022.

 

The EAACI Congress is the world's largest scientific conference specialising
in the field of allergy and clinical immunology and the flagship meeting of
the European Academy of Allergy and Clinical Immunology, an association of
more than 12,000 clinicians, researchers, and allied health professionals,
dedicated to improving the health of people affected by allergic diseases.

 

Among its 18 posters being presented, Allergy Therapeutics will share:

·     Further data from preclinical studies demonstrating the potential of
the Group's novel virus-like particle (VLP) based peanut allergy vaccine
candidate ("VLP Peanut") which will enter Phase I clinical evaluation later
this year

·    Detailed findings from the positive G309 exploratory field study which
evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course
subcutaneous allergen-specific immunotherapy (SCIT) candidate to address the
cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. These
findings supported the design of G306, Allergy Therapeutics' pivotal Phase III
trial, which is on track for commencement later this year

·    Preclinical and clinical studies examining the effect on pollen and
dust mite allergies of immunoBON, the Group's novel targeted micro-nutrition
FSMP (Food for Special Medical Purpose) which is based on the so-called
"protective farm effect"

 

Allergy Therapeutics will also be hosting two symposia during the congress:

·    A hybrid symposium, "Advancing Allergen Immunotherapy", taking place
today, Friday 1 July 2022, 13:15 - 14:45 CET, and chaired by Professor Erika
Jensen-Jarolim, MD, Clinical Immunologist, Division of Comparative
Medicine, Messerli Research Institute, Medical University of Vienna, will
consist of three presentations covering the optimisation of allergy
immunotherapy study design, innovative approaches to allergy field trials and
the potential of biomarker strategies in allergy immunotherapy trials.

·    A digital mini symposium, "MicroCrystalline Tyrosine-associated
allergoids: Reaching the top of the evidence pyramid", taking place on
Saturday 2 July 2022, 10:30 - 11:00 CET, presented by Professor
Ralph Mösges, Fellow of the American Academy of Allergy Asthma and
Immunology, Otorhinolaryngologist, Allergologist, University Hospital
Cologne, Germany.

 

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, commented:
"Allergy Therapeutics is committed to developing novel, short-course allergy
immunotherapies to transform patients' lives. With a strong presence at this
year's EAACI congress, where we are presenting 18 posters and hosting two
symposia, we are demonstrating the strength of our science and our commitment
to continued innovation. Our latest findings pave the way for the initiation
of two key clinical trials later this year - a Phase III trial of our
short-course grass pollen immunotherapy candidate, Grass MATA MPL, and the
Phase I PROTECT trial of our peanut allergy vaccine candidate, VLP Peanut."

 

The complete list of Allergy Therapeutics-sponsored abstracts accepted by
EAACI for presentation are available on the Group's website.

 

No new material price sensitive information is expected to be disclosed on
Allergy Therapeutics at the EAACI Congress 2022.

 

 

 Allergy Therapeutics' Hybrid Symposium

 Advancing Allergen Immunotherapy

 Friday 1 July 2022; 13:15 - 14:45 (CET)
 Introduction                                                                   Symposium Overview & Introductions

 Chair: Prof. Erika Jensen-Jarolim, MD, Clinical Immunologist, Division of
 Comparative Medicine, Messerli Research Institute, Medical University of
 Vienna, Austria
 Speaker                                                                        Optimisation of study design: What did we learn during

 Prof. Ludger Klimek, Head of the Center for Rhinology and Allergology,         the last decade?
 Wiesbaden, Germany
 Speaker:                                                                       Ground-breaking results of an exploratory AIT field trial:

 Prof. Stefan Zielen, Director and Senior Consultant at Frankfurt University    innovative approaches to succeed
 Hospital in the Department of Paediatrics, Germany
 Speaker:                                                                       Shaping the future of AIT trials based on novel

 Prof. Mohamed Shamji, Reader in Immunology & Allergy at Imperial College       biomarker strategies
 London, United Kingdom
 Chair: Dr. Ignacio Dávila, Assistant Professor of Allergy at University of     Q&A
 Salamanca, Spain
 Digital Company Sponsored Mini Symposium

 MicroCrystalline Tyrosine-associated allergoids: Reaching the top of the
 evidence pyramid

 Saturday 2nd July 2022; 10:30 - 11:00 (CET)
 Prof. Ralph Mösges, Fellow of the American Academy of Allergy Asthma and       MicroCrystalline Tyrosine-associated allergoids:
 Immunology, Otorhinolaryngologist, Allergologist, University Hospital

 Cologne, Germany                                                               Reaching the top of the evidence pyramid

 

 

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved over 9% compound annual growth since formation, employs c.600
employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASDSESSEESEEM